Payment overview · 2025
General Payments
$2,828.04
110 reported records · 18 companies
Healthcare provider profile · identity verified
Gary A Tigges, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PLANO, TX · NPI 1275576779
Verified facts
What the public records show
CMS Open Payments records show Gary A Tigges, MD received $2,828.04 in general payments during 2025 across 110 reported records.
ViiV Healthcare Company accounted for 32.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Dovato, Farxiga, Jardiance, Mounjaro, Ozempic, Pifeltro, Rukobia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Biktarvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Pifeltro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Dovato by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RUKOBIA as an associated drug or biological on 3367 records involving 1303 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rukobia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $910.15 | 32.2% | 32 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $484.38 | 17.1% | 17 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $319.74 | 11.3% | 13 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $290.20 | 10.3% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $246.52 | 8.7% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $121.82 | 4.3% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $76.28 | 2.7% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $73.40 | 2.6% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $57.98 | 2.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.21 | 1.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.24 | 1.7% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $31.55 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.72 | 0.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.68 | 0.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.38 | 0.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.87 | 0.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.04 | 0.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.88 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,828.04 | 110 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $389.98 | 14 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $319.74 | 13 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $290.20 | 8 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $234.92 | 9 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $210.10 | 10 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $162.85 | 6 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $147.22 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $73.40 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $73.40 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $73.40 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $57.98 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.82 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.82 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.21 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.21 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $49.24 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.85 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $39.84 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $31.55 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $23.72 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| O-ARM Normalized: o arm |
Device | Medtronic, Inc. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| DOVATO dovato |
2025 | Dovato | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 46 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 169 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 77 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 113 | exact normalized | Medicare Part D |
| PIFELTRO pifeltro |
2025 | Pifeltro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RUKOBIA rukobia |
2025 | Rukobia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
127 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
169 | 45 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
169 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
77 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
113 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | RUKOBIA open payments reported associated product |
CMS Open Payments — General Payments 3367 supporting records · 1303 recipient NPIs · example record 1189508926 |
Rukobia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 602 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 428 | 130 |
| Atorvastatin Calcium | Atorvastatin Calcium | 387 | 112 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 358 | 107 |
| Simvastatin | Simvastatin | 293 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 288 | 84 |
| Meloxicam | Meloxicam | 264 | 84 |
| Montelukast Sodium | Montelukast Sodium | 231 | 75 |
| Metformin Hcl | Metformin Hcl | 226 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 57 |
| Omeprazole | Omeprazole | 203 | 60 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 181 | 57 |
| Jardiance | Empagliflozin | 169 | 45 |
| Lisinopril | Lisinopril | 160 | 48 |
| Allopurinol | Allopurinol | 155 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 147 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 49 |
| Synthroid | Levothyroxine Sodium | 127 | 31 |
| Losartan Potassium | Losartan Potassium | 115 | 32 |
| Ozempic | Semaglutide | 113 | 36 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 112 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 36 |
| Ezetimibe | Ezetimibe | 94 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 24 |
| Potassium Chloride | Potassium Chloride | 90 | 27 |
| Sertraline Hcl | Sertraline Hcl | 90 | 25 |
| Mounjaro | Tirzepatide | 77 | 16 |
| Valsartan | Valsartan | 77 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 75 | 24 |
| Trazodone Hcl | Trazodone Hcl | 75 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 17 |
| Irbesartan | Irbesartan | 64 | 18 |
| Metformin Hcl Er | Metformin Hcl | 63 | 19 |
| Finasteride | Finasteride | 61 | 18 |
| Clonazepam | Clonazepam | 56 | 19 |
| Gabapentin | Gabapentin | 55 | 21 |
| Alprazolam | Alprazolam | 54 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 53 | 14 |
| Farxiga | Dapagliflozin Propanediol | 46 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 45 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Methylprednisolone | Methylprednisolone | 42 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 11 |
| Donepezil Hcl | Donepezil Hcl | 41 | 14 |
| Furosemide | Furosemide | 39 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 22 |
| Glipizide | Glipizide | 38 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 38 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 38 | 25 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 13 |
| Cefuroxime | Cefuroxime Axetil | 36 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 15 |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Carvedilol | Carvedilol | 34 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 11 |
| Glipizide Er | Glipizide | 34 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 33 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 29 |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 26 |
| Spironolactone | Spironolactone | 29 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 14 |
| Valacyclovir | Valacyclovir Hcl | 24 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 15 |
| Prednisone | Prednisone | 23 | 20 |
| Acyclovir | Acyclovir | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Estradiol | Estradiol | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 20 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Testosterone | Testosterone | 18 | 11 |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Pifeltro | Doravirine | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Etravirine | Etravirine | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Rukobia | Fostemsavir Tromethamine | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 11 | 11 |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,828.04 · 110 records | ViiV Healthcare Company | ABRYSVO, AIRSUPRA, APRETUDE, CABENUVA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, DOVATO, Dexcom G6 Transmitter, FARXIGA, GEMTESA, JARDIANCE, MOUNJARO, O-ARM, OTEZLA, Omnipod, Ozempic, PIFELTRO, PREVNAR 20, PROCLAIM, REPATHA, RUKOBIA, Rybelsus, UBRELVY, VOQUEZNA, ZEPBOUND, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Dovato play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error